Biotech, Food & Drug

HB Ad Slot
HB Mobile Ad Slot

In today’s hyper-aware environment, concerns about food and drug safety are paramount for both companies and consumers.  The Food and Drug Administration (FDA) and the US Department of Agriculture (USDA) regulates the areas of biotech, food, and drug law. Additionally, laws including the 21st Century Cures Act, and cGMP (Current Good Manufacturing Processes), regulate industry standards/norms in food, cosmetics, and other industry-sectors. Visitors to the National Law Review will find the latest analysis of news, legislation, and upcoming cases/litigation as it relates to this area of law.

With researchers searching for new energy solutions and other developments in biotech, visitors to the NLR will have the opportunity to read content surrounding biosimilars, natural fuel production, medical devices, biotechnology, nanotechnology and materials, and the pharmaceuticals industry. Additionally, content relating to food and drug laws, limits on chemical use in cosmetic products, and other general health/safety topics are covered by the National Law Review and are updated regularly. Additionally, food safety and imports to the United States are also discussed as they become relevant. 

In addition to general health, science, and food/drug, the industry is also closely related to many of the issues related to intellectual property law. New applications for patents, intellectual property, licensing laws, and other areas which are governed by the PTAB court, often crossover into the industry.

New developments in legislation, including the legalization of recreational marijuana has created a new area ripe for legal analysis.  Regulations on how recreational marijuana can be advertised and marketed, distributed and the kind of insurance coverage necessary for dispensaries.  Additionally, employer drug-testing and marijuana statutes have been a hot area of litigation covered by the National Law Review.  

General practices in marketing standards, compliance of federal and state laws/legislation, licensing collaborations, and news related to bringing new products to the market, in the US and abroad, are among the areas visitors to NLR will read about daily. Drug pricing, changes in production standards, regulatory compliance, food safety and handling, drug laws (legalization of marijuana, both recreational and medicinal in the workplace), and labeling and nutritional requirements, are among the many topics covered by the National Law Review daily.

Visitors will always find the latest, up-to-date, most comprehensive coverage on the site. And, news and stories which affect the US, companies which are regulated in the industry, and multinational/international companies, are detailed regularly for NLR readers.

National Law Review Cannabis TwitterFor hourly updates on the latest news about biotech, food & drug, and cannabis laws, regulations, and legislation, be sure to follow our Cannabis X (formerly Twitter) feed, and sign up for complimentary e-news bulletins.

Recent Biotechnology, Food & Drug Administration FDA News

Title
Publication Date Organization
Mar
3
2015
Details Of The European Commission’s Legal Analysis Of ‘Reverse Patent Settlement Agreements’ Revealed Covington & Burling LLP
Mar
2
2015
Drones May Soon Take Off in Agriculture Industry Barnes & Thornburg LLP
Mar
2
2015
Federal Circuit Upholds Patent Term Adjustment Deduction For IDS Filed After Restriction Requirement Foley & Lardner LLP
Mar
2
2015
NASDA Supports National Uniform Labeling Policy for Genetically Modified Foods --National Association of State Departments of Agriculture Varnum LLP
Mar
1
2015
A Second Look At The Innovation Act Obviousness Type Double Patenting Statute Foley & Lardner LLP
Feb
27
2015
Grants Available for Specialty Crops – March 26 Deadline Varnum LLP
Feb
27
2015
FDA Proposal to Regulate Laboratory Developed Tests Raises Legal Liability Questions for Labs Covington & Burling LLP
Feb
27
2015
FTC to Accelerate Oncology Drug Growth, Requires Novartis to Divest Two Protein Inhibitors in Its Clinical Development Pipeline Mintz
Feb
25
2015
The Court’s Decision in the FLANAX US Trademark Dispute Gives Bayer a Headache Mintz
Feb
24
2015
Pharmaceutical Uses Acquisition to Make Itself More Competitive McBrayer, McGinnis, Leslie and Kirkland, PLLC
Feb
24
2015
Early Signs of Continued Focus on Food Information, Authenticity and Traceability? Squire Patton Boggs (US) LLP
Feb
24
2015
CMS Takes a Measured Approach to Medicare Advantage and Part D Plan Payment Rates and Policy Changes for 2016: Increased Part D Drug Costs Set the Stage for Higher Beneficiary Premiums Epstein Becker & Green, P.C.
Feb
23
2015
FDA Issues Final Guidance Documents on Medical Device Data Systems and Medical Mobile Apps Barnes & Thornburg LLP
Feb
20
2015
Deja Vu All Over Again: Federal GMO Labeling Legislation Re-Introduced Mintz
Feb
19
2015
Go For De Novo: FDA’s Revised Approach to Medical Device Accessories Sheppard, Mullin, Richter & Hampton LLP
Feb
19
2015
Life Sciences: Protecting the Crown Jewels Sills Cummis & Gross P.C.
Feb
18
2015
M&A, Investment or Partnering Checklist for Medtech Companies Greenberg Traurig, LLP
Feb
18
2015
FDA Issues Guidance for Mobile Medical Applications: What Will be Subject to FDA Oversight and Enforcement? Sheppard, Mullin, Richter & Hampton LLP
Feb
18
2015
Device Manufacturer Settles False Claims Act Allegations with DOJ for $1.25 Million Mintz
Feb
18
2015
Growing Issues In A Miniature World: Nanomaterial Registers In The EU Squire Patton Boggs (US) LLP
Feb
16
2015
Revised Seed Law Expected to Come into Effect Soon in China Michael Best & Friedrich LLP
Feb
13
2015
DEA Rules On Disposal of Controlled Substances - What's Up? Poyner Spruill LLP
Feb
12
2015
Prescribing and Telemedicine: The “Physical” Exam Epstein Becker & Green, P.C.
Feb
12
2015
Interface without Regulation – FDA Deregulates MDDS and Related Technologies Sheppard, Mullin, Richter & Hampton LLP
Feb
12
2015
Medicare Fraud Plea in Detroit Pill Mill Case Mahany Law
Feb
12
2015
Filthy Pharma Chronicles – GVK Bio Fake Drug Trials Mahany Law
Feb
12
2015
Pharmaceutical Manufacturer Agrees to Pay U.S. Government $7.9 Million for Alleged Kickback Scheme Tycko & Zavareei LLP
Feb
11
2015
FDA Will Not Enforce Regulatory Controls for Medical Device Data Systems and Two Other Health IT Devices McDermott Will & Emery
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins